Neurocrine Biosciences (Neurocrine Biosciences) Total Inventories : $38 Mil (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is Neurocrine Biosciences Total Inventories?

Neurocrine Biosciences's total inventories for the quarter that ended in Dec. 2023 was $38 Mil. Neurocrine Biosciences's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $34 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Neurocrine Biosciences's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $3.66.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Neurocrine Biosciences's Days Inventory for the three months ended in Dec. 2023 was 360.17.

Inventory Turnover measures how fast the company turns over its inventory within a year. Neurocrine Biosciences's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.25.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Neurocrine Biosciences's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.07.

Neurocrine Biosciences Total Inventories Historical Data

The historical data trend for Neurocrine Biosciences's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurocrine Biosciences Total Inventories Chart

Neurocrine Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

17.30

28.00

30.50

35.10

38.30

Neurocrine Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															35.10	33.40	31.70	28.80	38.30

Neurocrine Biosciences Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Neurocrine Biosciences (NAS:NBIX) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Neurocrine Biosciences's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(1031.6	+	0.75 * 439.3	+	0.5 * 38.3	-	1019.4
-	0	-	0)	/	98.7
=	3.66

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Neurocrine Biosciences's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	33.55	/	8.5000000000001	*	365 / 4
	=	360.17

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Neurocrine Biosciences's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	8.5000000000001	/	33.55
	=	0.25

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Neurocrine Biosciences's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	33.55	/	515.2
	=	0.07

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Neurocrine Biosciences Total Inventories Related Terms

Thank you for viewing the detailed overview of Neurocrine Biosciences's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurocrine Biosciences (Neurocrine Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Neurocrine Biosciences Inc (NAS:NBIX) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

NB3:Germany NB3:Germany N1BI34:Brazil

Address

12780 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.neurocrine.com

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Executives

Kevin Charles Gorman	officer: Sr VP, Business Development	12790 EL CAMINO REAL, SAN DIEGO CA 92130
William H Rastetter	director	9885 TOWNE CENTRE DR., SAN DIEGO CA 92121
Kyle Gano	officer: Chief Business Dev Officer	NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Eiry Roberts	officer: Chief Medical Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130
Julie Cooke	officer: Chief Human Resources Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Gary A Lyons	director, officer: President and CEO	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Darin Lippoldt	officer: Chief Legal Officer	C/O VOLCANO CORPORATION, 3661 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Jude Onyia	officer: Chief Scientific Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
David W. Boyer	officer: Chief Corp. Affairs Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Ingrid Delaet	officer: Chief Regulatory Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92130
Matt Abernethy	officer: Chief Financial Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEGO CA 92121
Eric Benevich	officer: Chief Commerical Officer	C/O NEUROCRINE BIOSCIENCES, INC., 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Christine A Poon	director	C/O JOHNSON & JOHNSON, ONE JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Malcolm Lloyd-smith	officer: Chief Regulatory Officer	12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Stephen A Sherwin	director	C/O CELL GENESYS, INC., 500 FORBES BLVD., SOUTH SAN FRANCISCO CA 94080